Special Edition Recombinant Mouse Fabp4/a-fabp Protein (hek293, His Tag) Limited Time 95% Off [1yC4wRAx]

Special Edition Recombinant Mouse Fabp4/a-fabp Protein (hek293, His Tag) Limited Time 95% Off [1yC4wRAx]

Introducing our high-quality Recombinant Mouse FABP4/A-FABP Protein, a versatile research tool designed for a wide range of applications in molecular biology and biochemistry. This protein is produced in HEK293 cells and is tagged with a His Tag for easy purification. With its high purity and stable properties, this protein is ideal for use in various experiments, including ELISA, Western blot, and immunoprecipitation.

Product Specifications and Features

Our Recombinant Mouse FABP4/A-FABP Protein is offered with the following specifications: Synonyms include 422/aP2, ALBP/Ap2, Ap2, Lbpl; Species: Mouse; Expression Host: HEK293 Cells; Sequence: Met 1-Ala 132; Accession: NP_077717.1; Calculated Molecular Weight: 16 kDa; Observed Molecular Weight: 15 kDa; Tag: C-His. This protein has not been validated for activity but offers excellent purity, exceeding 85% as determined by reducing SDS-PAGE. It is also endotoxin-free, with less than 1.0 EU per μg of the protein as determined by the LAL method. The protein is lyophilized in sterile PBS, pH 7.4, with 5% - 8% trehalose, mannitol, and 0.01% Tween 80 added as protectants before lyophilization.

Applications and Benefits

This Recombinant Mouse FABP4/A-FABP Protein is a valuable tool for researchers studying lipid metabolism, obesity, and metabolic diseases. Its association with triglyceride-rich lipoproteins and its correlation with body mass index, triglycerides, and HDL-cholesterol concentrations make it an essential component in understanding atherogenic dyslipidemia. Additionally, its role in mediating sebaceous gland hyperplasia and its significance as a plasma marker of metabolic disturbances in HIV-infected patients highlight its potential in various research areas. With this protein, researchers can explore the complex mechanisms behind these conditions and develop new therapies for metabolic disorders.